Literature DB >> 7839075

Prevalence of antihuman parvovirus B19 IgG antibodies in patients with refractory rheumatoid arthritis and polyarticular juvenile rheumatoid arthritis.

A Mimori1, Y Misaki, T Hachiya, K Ito, S Kano.   

Abstract

We investigated the prevalence of antihuman parvovirus B19 immunoglobulin G (IgG) antibody in 108 Japanese patients with rheumatoid arthritis (RA) and 11 patients with polyarticular juvenile rheumatoid arthritis (JRA). Seropositivity of anti-B19 was significantly higher in patients with refractory RA (57.6%, 38/66) compared with patients with remittent RA (19.0%, 8/42; P < 0.001) or age-matched controls (24.3%, 19/78; P < 0.001). Patients with refractory polyarticular JRA had a significantly higher frequency of anti-B19 seropositivity (71.4%, 5/7) than age-matched controls (8.3%, 5/60; P < 0.001), while none of the remittent group was positive for the antibody (0/4).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7839075     DOI: 10.1007/bf00300807

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  17 in total

1.  The genome type of human parvovirus B19 strains isolated in Japan during 1981 differs from types detected in 1986 to 1987: a correlation between genome type and prevalence.

Authors:  K Umene; T Nunoue
Journal:  J Gen Virol       Date:  1990-04       Impact factor: 3.891

2.  An association between human parvovirus B-19 infection and autoantibody production.

Authors:  T Sasaki; Y Takahashi; K Yoshinaga; K Sugamura; H Shiraishi
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

3.  Human parvovirus B19 infection and juvenile chronic polyarthritis.

Authors:  T F Schwarz; M Roggendorf; H Suschke; F Deinhardt
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

4.  Human parvovirus and rheumatoid arthritis.

Authors:  J J Lefrere; O Meyer; C J Menkes; M J Beaulieu; A M Couroucé
Journal:  Lancet       Date:  1985-04-27       Impact factor: 79.321

5.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

6.  Human parvovirus infection in early rheumatoid and inflammatory arthritis.

Authors:  B J Cohen; M M Buckley; J P Clewley; V E Jones; A H Puttick; R K Jacoby
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

7.  Human parvovirus (B19) and erythema infectiosum.

Authors:  T Nunoue; K Okochi; P P Mortimer; B J Cohen
Journal:  J Pediatr       Date:  1985-07       Impact factor: 4.406

8.  Fine epitope mapping of the human SS-B/La protein. Identification of a distinct autoepitope homologous to a viral gag polyprotein.

Authors:  H Kohsaka; K Yamamoto; H Fujii; H Miura; N Miyasaka; K Nishioka; T Miyamoto
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

9.  Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis.

Authors:  J G Saal; M Steidle; H Einsele; C A Müller; P Fritz; J Zacher
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Human parvovirus arthropathy.

Authors:  D G White; A D Woolf; P P Mortimer; B J Cohen; D R Blake; P A Bacon
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

View more
  2 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Seroprevalence of parvovirus B19 IgG in children affected by juvenile idiopathic arthritis.

Authors:  Benedikt Weissbrich; Yvonne Süss-Fröhlich; Hermann J Girschick
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.